nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetohydroxamic Acid—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.0765	0.0776	CcSEcCtD
Acetohydroxamic Acid—Lethargy—Vandetanib—thyroid cancer	0.0494	0.0501	CcSEcCtD
Acetohydroxamic Acid—Depression—Vandetanib—thyroid cancer	0.0372	0.0377	CcSEcCtD
Acetohydroxamic Acid—Renal failure—Vandetanib—thyroid cancer	0.0367	0.0372	CcSEcCtD
Acetohydroxamic Acid—Alopecia—Vandetanib—thyroid cancer	0.0296	0.03	CcSEcCtD
Acetohydroxamic Acid—Tremor—Vandetanib—thyroid cancer	0.0273	0.0277	CcSEcCtD
Acetohydroxamic Acid—Abdominal discomfort—Sorafenib—thyroid cancer	0.027	0.0274	CcSEcCtD
Acetohydroxamic Acid—Renal failure—Sorafenib—thyroid cancer	0.0247	0.0251	CcSEcCtD
Acetohydroxamic Acid—Anxiety—Vandetanib—thyroid cancer	0.0247	0.0251	CcSEcCtD
Acetohydroxamic Acid—Feeling hot—Epirubicin—thyroid cancer	0.0212	0.0215	CcSEcCtD
Acetohydroxamic Acid—Decreased appetite—Vandetanib—thyroid cancer	0.0207	0.021	CcSEcCtD
Acetohydroxamic Acid—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0205	0.0208	CcSEcCtD
Acetohydroxamic Acid—Fatigue—Vandetanib—thyroid cancer	0.0205	0.0208	CcSEcCtD
Acetohydroxamic Acid—Alopecia—Sorafenib—thyroid cancer	0.02	0.0202	CcSEcCtD
Acetohydroxamic Acid—Feeling hot—Doxorubicin—thyroid cancer	0.0196	0.0199	CcSEcCtD
Acetohydroxamic Acid—Anaemia—Sorafenib—thyroid cancer	0.0182	0.0184	CcSEcCtD
Acetohydroxamic Acid—Asthenia—Vandetanib—thyroid cancer	0.0171	0.0173	CcSEcCtD
Acetohydroxamic Acid—Anorexia—Sorafenib—thyroid cancer	0.0153	0.0155	CcSEcCtD
Acetohydroxamic Acid—Vomiting—Vandetanib—thyroid cancer	0.0151	0.0153	CcSEcCtD
Acetohydroxamic Acid—Rash—Vandetanib—thyroid cancer	0.015	0.0152	CcSEcCtD
Acetohydroxamic Acid—Dermatitis—Vandetanib—thyroid cancer	0.015	0.0152	CcSEcCtD
Acetohydroxamic Acid—Headache—Vandetanib—thyroid cancer	0.0149	0.0151	CcSEcCtD
Acetohydroxamic Acid—Nausea—Vandetanib—thyroid cancer	0.0141	0.0143	CcSEcCtD
Acetohydroxamic Acid—Decreased appetite—Sorafenib—thyroid cancer	0.0139	0.0142	CcSEcCtD
Acetohydroxamic Acid—Thrombophlebitis—Epirubicin—thyroid cancer	0.0139	0.0141	CcSEcCtD
Acetohydroxamic Acid—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0139	0.0141	CcSEcCtD
Acetohydroxamic Acid—Fatigue—Sorafenib—thyroid cancer	0.0138	0.014	CcSEcCtD
Acetohydroxamic Acid—Thrombophlebitis—Doxorubicin—thyroid cancer	0.0129	0.0131	CcSEcCtD
Acetohydroxamic Acid—Renal impairment—Epirubicin—thyroid cancer	0.0127	0.0129	CcSEcCtD
Acetohydroxamic Acid—Lethargy—Epirubicin—thyroid cancer	0.0123	0.0125	CcSEcCtD
Acetohydroxamic Acid—Renal impairment—Doxorubicin—thyroid cancer	0.0117	0.0119	CcSEcCtD
Acetohydroxamic Acid—Asthenia—Sorafenib—thyroid cancer	0.0115	0.0117	CcSEcCtD
Acetohydroxamic Acid—Lethargy—Doxorubicin—thyroid cancer	0.0114	0.0116	CcSEcCtD
Acetohydroxamic Acid—Vomiting—Sorafenib—thyroid cancer	0.0102	0.0104	CcSEcCtD
Acetohydroxamic Acid—Rash—Sorafenib—thyroid cancer	0.0101	0.0103	CcSEcCtD
Acetohydroxamic Acid—Dermatitis—Sorafenib—thyroid cancer	0.0101	0.0103	CcSEcCtD
Acetohydroxamic Acid—Headache—Sorafenib—thyroid cancer	0.0101	0.0102	CcSEcCtD
Acetohydroxamic Acid—Nausea—Sorafenib—thyroid cancer	0.00953	0.00967	CcSEcCtD
Acetohydroxamic Acid—Renal failure—Epirubicin—thyroid cancer	0.00914	0.00927	CcSEcCtD
Acetohydroxamic Acid—Renal failure—Doxorubicin—thyroid cancer	0.00846	0.00858	CcSEcCtD
Acetohydroxamic Acid—Alopecia—Epirubicin—thyroid cancer	0.00738	0.00748	CcSEcCtD
Acetohydroxamic Acid—Tension—Epirubicin—thyroid cancer	0.00713	0.00723	CcSEcCtD
Acetohydroxamic Acid—Nervousness—Epirubicin—thyroid cancer	0.00706	0.00716	CcSEcCtD
Acetohydroxamic Acid—Alopecia—Doxorubicin—thyroid cancer	0.00682	0.00692	CcSEcCtD
Acetohydroxamic Acid—Ill-defined disorder—Epirubicin—thyroid cancer	0.00674	0.00684	CcSEcCtD
Acetohydroxamic Acid—Anaemia—Epirubicin—thyroid cancer	0.00672	0.00681	CcSEcCtD
Acetohydroxamic Acid—Tension—Doxorubicin—thyroid cancer	0.0066	0.00669	CcSEcCtD
Acetohydroxamic Acid—Malaise—Epirubicin—thyroid cancer	0.00655	0.00665	CcSEcCtD
Acetohydroxamic Acid—Nervousness—Doxorubicin—thyroid cancer	0.00653	0.00662	CcSEcCtD
Acetohydroxamic Acid—Palpitations—Epirubicin—thyroid cancer	0.00642	0.00651	CcSEcCtD
Acetohydroxamic Acid—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00624	0.00633	CcSEcCtD
Acetohydroxamic Acid—Anaemia—Doxorubicin—thyroid cancer	0.00621	0.0063	CcSEcCtD
Acetohydroxamic Acid—Anxiety—Epirubicin—thyroid cancer	0.00616	0.00625	CcSEcCtD
Acetohydroxamic Acid—Discomfort—Epirubicin—thyroid cancer	0.00611	0.0062	CcSEcCtD
Acetohydroxamic Acid—Malaise—Doxorubicin—thyroid cancer	0.00606	0.00615	CcSEcCtD
Acetohydroxamic Acid—Palpitations—Doxorubicin—thyroid cancer	0.00594	0.00603	CcSEcCtD
Acetohydroxamic Acid—Anxiety—Doxorubicin—thyroid cancer	0.0057	0.00579	CcSEcCtD
Acetohydroxamic Acid—Discomfort—Doxorubicin—thyroid cancer	0.00565	0.00574	CcSEcCtD
Acetohydroxamic Acid—Anorexia—Epirubicin—thyroid cancer	0.00565	0.00573	CcSEcCtD
Acetohydroxamic Acid—Anorexia—Doxorubicin—thyroid cancer	0.00523	0.00531	CcSEcCtD
Acetohydroxamic Acid—Decreased appetite—Epirubicin—thyroid cancer	0.00515	0.00523	CcSEcCtD
Acetohydroxamic Acid—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00512	0.00519	CcSEcCtD
Acetohydroxamic Acid—Fatigue—Epirubicin—thyroid cancer	0.00511	0.00519	CcSEcCtD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—CITED1—thyroid cancer	0.00496	0.343	CbGpPWpGaD
Acetohydroxamic Acid—Feeling abnormal—Epirubicin—thyroid cancer	0.00489	0.00496	CcSEcCtD
Acetohydroxamic Acid—Decreased appetite—Doxorubicin—thyroid cancer	0.00477	0.00484	CcSEcCtD
Acetohydroxamic Acid—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00474	0.00481	CcSEcCtD
Acetohydroxamic Acid—Fatigue—Doxorubicin—thyroid cancer	0.00473	0.0048	CcSEcCtD
Acetohydroxamic Acid—Feeling abnormal—Doxorubicin—thyroid cancer	0.00452	0.00459	CcSEcCtD
Acetohydroxamic Acid—Asthenia—Epirubicin—thyroid cancer	0.00425	0.00432	CcSEcCtD
Acetohydroxamic Acid—Asthenia—Doxorubicin—thyroid cancer	0.00394	0.00399	CcSEcCtD
Acetohydroxamic Acid—Vomiting—Epirubicin—thyroid cancer	0.00377	0.00383	CcSEcCtD
Acetohydroxamic Acid—Rash—Epirubicin—thyroid cancer	0.00374	0.00379	CcSEcCtD
Acetohydroxamic Acid—Dermatitis—Epirubicin—thyroid cancer	0.00374	0.00379	CcSEcCtD
Acetohydroxamic Acid—Headache—Epirubicin—thyroid cancer	0.00371	0.00377	CcSEcCtD
Acetohydroxamic Acid—Nausea—Epirubicin—thyroid cancer	0.00352	0.00357	CcSEcCtD
Acetohydroxamic Acid—Vomiting—Doxorubicin—thyroid cancer	0.00349	0.00354	CcSEcCtD
Acetohydroxamic Acid—Rash—Doxorubicin—thyroid cancer	0.00346	0.00351	CcSEcCtD
Acetohydroxamic Acid—Dermatitis—Doxorubicin—thyroid cancer	0.00346	0.00351	CcSEcCtD
Acetohydroxamic Acid—Headache—Doxorubicin—thyroid cancer	0.00344	0.00349	CcSEcCtD
Acetohydroxamic Acid—Nausea—Doxorubicin—thyroid cancer	0.00326	0.00331	CcSEcCtD
Acetohydroxamic Acid—MMP12—Spinal Cord Injury—LGALS3—thyroid cancer	0.00199	0.138	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—Spinal Cord Injury—CDK1—thyroid cancer	0.00136	0.0942	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—Extracellular matrix organization—LAMA2—thyroid cancer	0.00127	0.0881	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—CDK1—thyroid cancer	0.00124	0.0861	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—TERT—thyroid cancer	0.000896	0.0621	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—Spinal Cord Injury—PTGS2—thyroid cancer	0.000627	0.0434	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—Spinal Cord Injury—CCND1—thyroid cancer	0.000566	0.0392	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—CCND1—thyroid cancer	0.000518	0.0359	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—Spinal Cord Injury—TP53—thyroid cancer	0.000373	0.0259	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—TP53—thyroid cancer	0.000341	0.0236	CbGpPWpGaD
Acetohydroxamic Acid—MMP12—TGF-beta Signaling Pathway—AKT1—thyroid cancer	0.000288	0.02	CbGpPWpGaD
